Reveal Genomics and Ona Therapeutics partner to accelerate the clinical development of ONA-255, an antibody-drug conjugate targeting common solid tumors. Dr. Aleix Prat leads the collaboration, focusing on biomarker analysis to enhance therapy efficacy.